Gara Edit, Ong Sang-Ging, Winkler Johannes, Zlabinger Katrin, Lukovic Dominika, Merkely Bela, Emmert Maximilian Y, Wolint Petra, Hoerstrup Simon P, Gyöngyösi Mariann, Wu Joseph C, Pavo Noemi
Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Front Bioeng Biotechnol. 2022 May 12;10:767985. doi: 10.3389/fbioe.2022.767985. eCollection 2022.
Recent preclinical investigations and clinical trials with stem cells mostly studied bone-marrow-derived mononuclear cells (BM-MNCs), which so far failed to meet clinically significant functional study endpoints. BM-MNCs containing small proportions of stem cells provide little regenerative potential, while mesenchymal stem cells (MSCs) promise effective therapy paracrine impact. Genetic engineering for rationally enhancing paracrine effects of implanted stem cells is an attractive option for further development of therapeutic cardiac repair strategies. Non-viral, efficient transfection methods promise improved clinical translation, longevity and a high level of gene delivery. Hypoxia-induced factor 1α is responsible for pro-angiogenic, anti-apoptotic and anti-remodeling mechanisms. Here we aimed to apply a cellular gene therapy model in chronic ischemic heart failure in pigs. A non-viral circular minicircle DNA vector (MiCi) was used for transfection of porcine MSCs (pMSC) with HIF1α (pMSC-MiCi-HIF-1α). pMSCs-MiCi-HIF-1α were injected endomyocardially into the border zone of an anterior myocardial infarction one month post-reperfused-infarct. Cell injection was guided 3D-guided NOGA electro-magnetic catheter delivery system. pMSC-MiCi-HIF-1α delivery improved cardiac output and reduced myocardial scar size. Abundances of pro-angiogenic proteins were analyzed 12, 24 h and 1 month after the delivery of the regenerative substances. In a protein array, the significantly increased angiogenesis proteins were Activin A, Angiopoietin, Artemin, Endothelin-1, MCP-1; and remodeling factors ADAMTS1, FGFs, TGFb1, MMPs, and Serpins. In a qPCR analysis, increased levels of angiopeptin, CXCL12, HIF-1α and miR-132 were found 24 h after cell-based gene delivery, compared to those in untreated animals with infarction and in control animals. Expression of angiopeptin increased already 12 h after treatment, and miR-1 expression was reduced at that time point. In total, pMSC overexpressing HIF-1α showed beneficial effects for treatment of ischemic injury, mediated by stimulation of angiogenesis.
近期针对干细胞的临床前研究和临床试验大多聚焦于骨髓来源的单核细胞(BM-MNCs),但迄今为止,这些研究未能达到具有临床意义的功能研究终点。含有少量干细胞的BM-MNCs再生潜力有限,而间充质干细胞(MSCs)有望通过旁分泌作用实现有效治疗。通过基因工程合理增强植入干细胞的旁分泌效应,是进一步发展治疗性心脏修复策略的一个有吸引力的选择。非病毒、高效的转染方法有望改善临床转化、延长寿命并实现高水平的基因递送。缺氧诱导因子1α负责促血管生成、抗凋亡和抗重塑机制。在此,我们旨在将细胞基因治疗模型应用于猪的慢性缺血性心力衰竭。使用非病毒环状微环DNA载体(MiCi)将猪间充质干细胞(pMSC)转染HIF1α(pMSC-MiCi-HIF-1α)。在心肌梗死后再灌注一个月,将pMSCs-MiCi-HIF-1α经心内膜注射到前壁心肌梗死的边缘区。细胞注射通过三维引导的NOGA电磁导管输送系统进行。pMSC-MiCi-HIF-1α的递送改善了心输出量并减小了心肌瘢痕大小。在递送再生物质后的12小时、24小时和1个月分析促血管生成蛋白的丰度。在蛋白质阵列中,显著增加的血管生成蛋白有激活素A、血管生成素、Artemin、内皮素-1、单核细胞趋化蛋白-1;以及重塑因子ADAMTS1、成纤维细胞生长因子、转化生长因子β1、基质金属蛋白酶和丝氨酸蛋白酶抑制剂。在定量聚合酶链反应分析中,与未治疗的梗死动物和对照动物相比,基于细胞的基因递送24小时后发现血管肽、CXCL12、HIF-1α和miR-132水平升高。治疗后12小时血管肽表达即已增加,此时miR-1表达降低。总体而言,过表达HIF-1α的pMSC对缺血性损伤的治疗显示出有益效果,这是通过刺激血管生成介导的。